SCHEMBL6955005

SCHEMBL6955005

COc1cc2oc(=O)c(C)c(C)c2cc1OCCN1CCN(c2cccc3ccc(C)nc23)CC1.Cc1ccc2cccc(N3CCNCC3)c2n1

nearest known ligand 0.62

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
PDE3B Q13370 1/20 0.43
PDE3A Q14432 1/20 0.43
ABCB1 P08183 1/20 0.41
ABCC1 P33527 1/20 0.41
DRD2 P14416 3/20 0.40
HTR2A P28223 1/20 0.40
ADRA1A P35348 1/20 0.40
KCNH2 Q12809 1/20 0.40
DRD3 P35462 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6954016 0.96 DRD2 (0.45) ABCB1ABCC1DRD2HTR2AADRA1A
SCHEMBL6736538 0.96 ABCB1 (0.44) ABCB1ABCC1DRD2HTR2AADRA1A
Hydrochloric Acid SCHEMBL6944579 0.95 ABCB1 (0.44) ABCB1ABCC1DRD2HTR2AADRA1A
Hydrochloric Acid SCHEMBL6740408 0.94 ABCB1 (0.43) ABCB1ABCC1DRD2HTR2AADRA1A
SCHEMBL6735246 0.92 DRD2 (0.47) ABCB1ABCC1DRD2HTR2AADRA1A
SCHEMBL6955839 0.92 HTR2A (0.47) PDE3BPDE3AABCB1ABCC1DRD2
Hydrochloric Acid SCHEMBL6948459 0.91 DRD2 (0.47) ABCB1ABCC1DRD2HTR2AADRA1A
Hydrochloric Acid SCHEMBL6738843 0.91 DRD2 (0.46) DRD2HTR2AADRA1AKCNH2DRD3
SCHEMBL6955657 0.88 HTR7 (0.47) DRD2HTR2AADRA1ADRD3
SCHEMBL6734946 0.87 HTR7 (0.47) ABCB1ABCC1DRD2HTR2AADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1311503-A1 CHROMENONE DERIVATIVES AND THEIR USE FOR TREATING DISEASES IN CONJUNCTION WITH 5-HTA1 RECEPTORS AND/OR DOPAMINE D2 RECEPTORS MERCK PATENT GmbH (DE) 2003-05-21 EP disclosed
WO-2002016354-A1 CHROMENONE DERIVATIVES AND THEIR USE FOR TREATING DISEASES IN CONJUNCTION WITH 5-HTA1 RECEPTORS AND/OR DOPAMINE D2 RECEPTORS MERCK PATENT GMBH (DE) 2002-02-28 WO disclosed